c-kit expression in adenocarcinomas of the lung

Tumor Biology

Volumn 25, Issue 5-6, 2004, Pages 235-342

  Micke, Patrick ^b,d   Hengstler, Jan Georg ^a   Albrecht, Heidi ^b   Faldum, Andreas ^c   Bittinger, Fernando ^c   Becker, Kai ^b   Wiewrodt, Rainer ^b   Fischer, Berthold ^b   Buhl, Roland ^b  

^a Rudolf Boehm Inst Pharmacol T   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

Adenocarcinoma; c kit; Glivec; Imatinib; Lung cancer; Non small cell lung cancer; Prognosis; Receptor tyrosine kinase; STI571

Indexed keywords

POLYCLONAL ANTIBODY; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; FREQUENCY ANALYSIS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PARAMETER; PATIENT SELECTION; PERFORMANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STAINING; STATISTICAL SIGNIFICANCE; TECHNIQUE; VARIANCE;

EID: 11444265409     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081386     Document Type: Review

References (43)

1. Janssen-Heijnen ML, Coebergh JW: The changing epidemiology of lung cancer in Europe. Lung Cancer 2003;41:245-258.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
3. Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
4. Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313.
5. Micke P, Basrai M, Faldum A, Bittinger F, Ronnstrand L, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R, Hengstler JG: Characterization of c-kit expression in small cell lung cancer: Prognostic and therapeutic implications. Clin Cancer Res 2003;9:188-194.
6. Micke P, Hengstler JG, Ros R, Bittinger F, Metz T, Gebhard S, Beeh KM, Oesch F, Buhl R: C-erbB-2 expression in small cell lung cancer is associated with poor prognosis. Int J Cancer 2001;92:474-479.
7. Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N, Nishio K: Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFRTKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 2002;98:310-315.
8. Hengstler JG, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B: Contribution of c-erbB-2 and topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res 1999;59:3206-3214.
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
10. Keri G, Balogh A, Teplan I, Csuka O: Comparison of the tyrosine kinase activity with the proliferation rate in human colon solid tumors and tumor cell lines. Tumour Biol 1988;9:315-322.
11. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
12. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-914.
13. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
14. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001;358:1421-1423.
15. Heinrich MC, Blanke CD, Druker BJ, Corless CL: Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-1703.
16. Goldman JM: Tyrosine-kinase inhibition in treatment of chronic myeloid leukemia. Lancet 2000;355:1031-1032.
17. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L, Snyder HW Jr, Brodeur D, Zuckerman EE, Hardy WD: A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320:415-421.
18. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-3351.
19. Geissler EN, Ryan MA, Housman DE: The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988;55:185-192.
20. Ashman LK: The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999;31:1037-1051.
21. Sekido Y, Takahashi T, Ueda R, Takahashi M, Suzuki H, Nishida K, Tsukamoto T, Hida T, Shimokata K, Zsebo KM: Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit proto-oncogene. Cancer Res 1993;53:1709-1714.
22. Krystal GW, Hines SJ, Organ CP: Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996;56:370-376.
23. von Mach MA, Schlosser J, Weiland M, Feilen PJ, Ringel M, Hengstler JG, Weilemann LS, Beyer J, Kann P, Schneider S: Cryopreservation of islets of Langerhans: Optimization of protocols. EXCLI J 2003;2:6-21.
24. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 1997,111:1710-1717.
25. Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, Buhl R: Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - What limits limited disease? Lung Cancer 2002;37:271-276.
26. Araki K, Ishii G, Yokose T, Nagai K, Funai K, Kodama K, Nishiwaki Y, Ochiai A: Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2003;40:173-180.
27. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A: Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992;52:6139-6143.
28. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A: Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992;52:197-201.
29. Parrott JA, Kim G, Skinner MK: Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod 2000;62:1600-1609.
30. Toyota M, Hinoda Y, Takaoka A, Makiguchi Y, Takahashi T, Itoh F, Imai K, Yachi A: Expression of c-kit and kit ligand in human colon carcinoma cells. Tumour Biol 1993;14:295-302.
31. Krystal GW, Honsawek S, Litz J, Buchdunger E: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-3326.
32. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000;19:3521-3528.
33. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T: Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003;9:5880-5887.
34. Pietsch T, Nicotra MR, Fraioli R, Wolf HK, Mottolese M, Natali PG: Expression of the c-Kit receptor and its ligand SCF in non-smallcell lung carcinomas. Int J Cancer 1998;75:171-175.
35. Matsuda R, Takahashi T, Nakamura S, Sekido Y, Nishida K, Seto M, Seito T, Sugiura T, Ariyoshi Y, Takahashi T, et al: Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993;142:339-346.
36. Lonardo F, Pass HI, Lucas DR: Immunohistochemistry frequently detects c-Kit expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy. Appl Immunohistochem Mol Morphol 2003;11:51-59.
37. Dimitrijevic S, Moricz M, Kowalski M, Kiese B, Proot P, Nikolova Z, Silberman S: A rational designed, targeted tumor treatment approach: A phase II study of Glivec (formerly STI571) in patients with life threatening diseases known to be associated with Glivec-sensitive tyrosine kinases. Molecular Targets and Cancer Therapeutics, Proceedings of the International Conference, Miami, 2001, A378.
38. Takanami I, Tanana F, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T, Kodaira S: Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: An evaluation of their expression as prognostic markers. Oncology 1996;53:392-397.
39. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, Paesmans M, Steels E, Verdebout JM, Sculier JP: The role of EGFR expression on patient survival in lung cancer: A systematic review with meta-analysis. Eur Respir J 2002;20:975-981.
40. Hirsch FR, Franklin WA, Bunn PA: What is the role of HER-2/neu and trastuzumab (Herceptin) in lung cancer? Lung Cancer 2002;36:263-264.
41. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794.
42. Wilkinson E: Surprise phase III failure for ZD1839. Lancet Oncol 2002;3:583.
43. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, Kitamura Y: Gain-offunction mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001;193:505-510.